APSR2026-989

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-027
P69
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1212842-46904-APSR Poster - 20261016 -v1_433560.pdf
Format: PDF Only
09. Asthma
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Clara Hon-Ying Tsai - AstraZeneca Taiwan Ltd Medical Department Taipei Taiwan
Kai-Cheng Chang - Chang Gung Memorial Hospital Department of Pharmacy Taoyuan Taiwan
Hui-Yu Chen - Chang Gung Memorial Hospital Department of Pharmacy Taoyuan Taiwan
Po-Jui Chang * Chang Gung Memorial Hospital Department of Thoracic Medicine Taoyuan Taiwan
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Po-Jui
Chang
playchang5478@gmail.com
+886917624377
31-40
Taiwan
Original Research
Real-World Prescription Pattern of Biologic Agents among Severe Asthma Patients: A multi-institutional Study in Taiwan
Maximum 25 words
Abstract Content
Biologic agents targeting distinct inflammatory pathways - including anti-IgE (omalizumab), anti-IL-5/5R (mepolizumab, benralizumab), anti-IL-4Rα (dupilumab), and anti-TSLP (tezepelumab) - have revolutionized severe asthma management. Nevertheless, optimal biologic selection and long-term treatment adherence remain challenging in clinical practice. This multicenter study investigated real-world patterns of biologic utilization, treatment persistence, and clinical outcomes in Taiwanese patients with severe asthma.
A retrospective cohort analysis was performed using electronic health records from multiple hospitals across Taiwan. Eligible participants included those with severe asthma who commenced their initial biologic therapy between January 2017 and March 2024. Severe asthma classification required documented use of medium or high-dose inhaled corticosteroids (ICS) and long-acting β adrenoceptor agonist (LABA) for a minimum of 12 months preceding biologic initiation. The primary outcome was drug survival, defined by discontinuation of initiation biologics, or switching to other biologics.
Among 742 patients (median follow-up: 41.5 months), omalizumab was most frequently initiated (60.0%), followed by mepolizumab (19.8%), benralizumab (13.5%), dupilumab (4.6%), and tezepelumab (2.2%), reflecting sequential market availability with increasing utilization trends for mepolizumab, benralizumab, dupilumab and tezepelumab over the study period. Baseline phenotypes varied significantly by biologic mechanism: anti-IL-5/5R recipients had higher eosinophil counts (4.62–4.64% vs. 3.20% for omalizumab, p<0.001). Baseline FEV₁ ranged from 1.33 L (tezepelumab) to 2.16 L (dupilumab, p=0.0065); ACT scores were comparable across groups (18.62–21.20, p=0.09). One-year drug survival rate was comparable between groups, and mepolizumab had the highest drug failure rate at the end of follow-up (omalizumab 13.0%, mepolizumab 21.8%, benralizumab 13.7%, dupilumab 14.3%).
Distinct baseline phenotypes across biologic mechanisms suggest phenotype-guided treatment selection in clinical practice. High persistence and low switching rates indicate favorable real-world effectiveness. Prospective studies validating predictive biomarkers are warranted.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Severe asthma. Biologic therapy. Treatment persistence
maximum 3 keywords and no abbreviations, separated by commas
Funding: This study was sponsored by AstraZeneca.
300